CYP3A4⁎22 gene polymorphism and risk of ischemic stroke in south Iran population: A case control study

Autor: Bita Divsalar, Tahereh Kalantari, Ardeshir Bahmanimehr, Afshin Borhani-Haghighi, Gholamreza Rafiei Dehbidi, Soheila Mohebbi
Rok vydání: 2021
Předmět:
Zdroj: Meta Gene. 29:100932
ISSN: 2214-5400
DOI: 10.1016/j.mgene.2021.100932
Popis: Cytochrome P450 3A4 (CYP3A4), the main drug-metabolizing enzyme in the liver, has a functional SNP in intron six named CYP3A4⁎22. Given the CYP3A4⁎22 polymorphism effect on the reduced CYP3A4 mRNA/protein expression, this study aimed to evaluate the prevalence of CYP3A4⁎22 polymorphism in Iranian patients with stroke compared to the control group. A total of 175 patients with stroke and 236 control age-sex matched ones have been examined for CYP3A4⁎22 polymorphism by Tetra ARMS-PCR methods. The results were confirmed by the PCR-RFLP technique and the sequencing of DNA. This study is the first report of CYP3A4⁎22 polymorphism from Iran. The frequency of the CYP3A4⁎22 wild-type (GG genotype) and heterozygous genotypes (GA genotype) was 93.1% and 6.9% in patients, and 92.8% and 7.2% in the controls, respectively. None of the participants was the recessive model for this polymorphism. There were no statistical differences between the patient and control groups (p > 0.05). Also, the GA genotype was not associated with increased risk of stroke compared with the GG genotype (OR = 0.95, 95% CI: 0.44–2.04, P = 0.892). Since CYP3A4⁎22 polymorphism may result in reduced CYP3A4 activity in vivo, due to the large number of drugs that are CYP3A4 substrates, individuals with this polymorphism may experience unusual drug effects. To clarify these impacts, further investigations are, therefore, needed to be done.
Databáze: OpenAIRE
Externí odkaz: